Retrospective comparative analysis of cardiovascular implantable electronic device infections with and without the use of antibacterial envelopes
Related Experiment Video
Updated: Mar 8, 2026

An In Vitro Model of a Parallel-Plate Perfusion System to Study Bacterial Adherence to Graft Tissues
Published on: January 7, 2019
A Hassoun1, E D Thottacherry1, M Raja1
1Department of Infectious Disease, Alabama Infectious Diseases Center, Huntsville, AL, USA.
Background:
Cardiovascular implantable electronic device (CIED) infections are associated with morbidity and mortality. Peri-operative systemic intravenous antibiotic prophylaxis reduces the rate of CIED infections. AIGISRx, a polymer envelope implanted with the CIED, releases minocycline and rifampin, and has been introduced to reduce infections.
Methods:
Retrospective review of 184 patients who underwent CIED implantation was conducted. Ninety-two patients were implanted with an AIGISRx envelope (AIGISRx group) and 92 patients were not implanted with an AIGISRx envelope (control group). Data were collected on demographics and risk factors for CIED infections (i.e. congestive heart failure, renal insufficiency, chronic kidney disease, oral anticoagulant use, chronic steroid use, need for lead replacement or revision, temporary pacing, early re-intervention, and having more than two leads in place). Rates of implantation success, major infections and mortality were compared between the AIGISRx group and the control group.
Results:
The AIGISRx group had longer hospitalizations (6.8±10.7 days vs 3.1±5.2 days; P=0.001), higher chronic corticosteroid use, higher rates of replacement or revision (51.1% vs 8.7%; P=0.001), and a greater proportion of devices with more than two intracardiac leads (42.4% vs 29.3%; P=0.03) than the control group. Successful implantation occurred in 97% of patients in both groups. Major infection was seen in 5.4% of cases in the AIGISRx group and 1.1% of cases in the control group (P=0.048). Device removal was conducted in 3.3% of cases in the AIGISRx group compared with 1.1% of cases in the control group (P=0.16). There were two deaths in the AIGISRx group. Organisms cultured were meticillin-resistant Staphylococcus aureus, meticillin-susceptible S. aureus and Enterococcus faecalis.
Conclusion:
The AIGISRx group had higher rates of major infection but also higher risk factors compared with the control group. The rate of device extraction and CIED-related mortality was higher in the AIGISRx group than in the control group.
Insights
Cardiovascular implantable electronic device (CIED) infections are a serious concern. The AIGISRx envelope did not reduce CIED infections and was associated with higher infection and mortality rates in this study.
Area of Science:
- Cardiology
- Infectious Diseases
- Biomaterials
Background:
- Cardiovascular implantable electronic device (CIED) infections pose significant risks.
- Systemic antibiotic prophylaxis is standard for reducing CIED infections.
- AIGISRx is a novel antibiotic-eluting envelope designed to prevent CIED infections.
Purpose of the Study:
- To evaluate the efficacy of the AIGISRx envelope in preventing CIED infections.
- To compare infection rates, implantation success, and mortality between patients with and without the AIGISRx envelope.
Main Methods:
- A retrospective review of 184 patients undergoing CIED implantation.
- Comparison of 92 patients with AIGISRx (AIGISRx group) versus 92 patients without (control group).
- Analysis of demographics, risk factors, implantation success, infection rates, and mortality.
Main Results:
- Both groups had a 97% successful implantation rate.
- The AIGISRx group experienced significantly higher rates of major infection (5.4% vs 1.1%) and longer hospitalizations.
- The AIGISRx group also showed higher rates of device replacement/revision and mortality.
Conclusions:
- The AIGISRx envelope was associated with increased rates of major infection and mortality.
- Patients receiving AIGISRx had more complex procedures and higher pre-existing risk factors.
- Further investigation is needed to understand the role of AIGISRx in CIED infection prevention.
Related Concept Videos
Bacterial Signaling
Endocarditis III: Medical Management
Endocarditis I: Introduction
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...

